Intrexon Corporation Appoints Dr. Kelly Huang As Head Of Newly Established Consumer Sector

GERMANTOWN, Md., March 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Kelly Huang, Ph.D., most recently President of HealthTronics, Inc., a subsidiary of Endo Health Solutions, to head the Company's newly established Consumer Sector. Dr. Huang will join Intrexon effective March 17, reporting to Chairman and Chief Executive Officer Randal J. Kirk. Through its Consumer Sector, Intrexon will expand its programs employing novel biologically-based solutions for consumer markets using the Company's integrated synthetic biology technologies and expertise.

Dr. Huang brings to Intrexon more than 18 years experience leading global businesses in life sciences and consumer healthcare. Dr. Huang joins Intrexon from Endo Health Solutions where he was a member of the Executive Committee responsible for strategic leadership across multiple sectors and was President of the Medical Services Division, HealthTronics, since 2011. Dr. Huang has spent the majority of his career with the Johnson & Johnson Family of Companies, where he led award-winning product launches in cosmetic and over-the-counter consumer products as Vice President of Research & Development and corporate officer of Neutrogena Corporation. As Vice President of J&J's Development Corporation from 2006 through 2009, he established and headed an Internal Venture to partner with a synthetic biology company toward development of a transformational delivery platform based upon novel protein conjugates. Dr. Huang also held leadership positions within J&J's Consumer Healthcare Business, which included spending 2 years in Paris, France, that drove innovation globally.

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon commented, "Kelly's ability to integrate scientific, consumer, and professional insights to create value by putting the customer at the center of business innovation makes him a great addition to our team as Intrexon applies synthetic biology to the consumer space. As a scientist, engineer, manager and veteran in consumer product development, he is ideally suited to his new role in our corporation. The Intrexon team looks forward to working with Kelly as he applies our technologies in support of existing consumer-driven collaborations such as J&J and expands our business in this sector."

Dr. Huang added, "The single gene approaches of biotechnology to date have had minimal impact on consumer products. Intrexon's novel integration of engineering controls with systems biology offers a unique approach to the complexity required for biologically-based solutions to meet consumer needs. I am energized by the potential of my new position as Intrexon cultivates new collaborations in this area and utilizes synthetic biology for the development of products that improve the lives of consumers everyday."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Consumer, and the Environment to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Intrexon Corporate Contact
Marie L. Rossi, Ph.D.
Manager, Technical Communications
Tel. +1 (301) 556-9944
Email: [email protected]

SOURCE Intrexon Corporation